NCT04804865

Secondary Prognostic Index in RefrActory Lymphoma

Secondary Prognostic Index in RefrActory Diffuse Large B Cells Lymphoma

• Status: Unknown
• Phase: —
• Study type: Observational
• Enrollment: 180 (estimated)
• Sponsor: Weprom · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

60% of patients with diffuse large B cell lymphoma are healed after first-line treatment which whatever the age. For the remaining 40% of patients (relapses and primary refractories): * 38% of patients will be cured with a 2nd line including an autologous haematopoietic cell transplantation for those under 65 years. * for older patients who are not eligible for a autograft: only 70% of patients will be able to receive 2nd line treatment with rates response less than 50%. * the survival rate in patients receiving 3rd line treatment or more is 15% at 2 years. Actually, no standard of chemotherapy is offered to relapsed or refractory patients after 2 therapeutic lines. Subsequent lines lead to hospitalizations for infectious complications or transfusions without clear clinical benefit with often an impacted quality of life. Palliative care is rarely offered as part of the treatment overall load.

Conditions

• Diffuse Large B Cell Lymphoma
• Refractory Diffuse Large B-Cell Lymphoma

Interventions

Type	Name	Description
OTHER	prognostic assessment	determination of a prognostic score with 3 clinical and 5 biological parameters.

Timeline

• Start date: 2020-01-01
• Primary completion: 2022-06-01
• Completion: 2022-06-01
• First posted: 2021-03-18
• Last updated: 2021-03-23

Locations

2 sites across 1 country: France